The average age of registered nurses was 47.9 years old in 2018, and
47.5 percent of RNs were 50 or older, according to a new HHS report.
The findings are based on a 2018 survey of 50,273 RNs by the National
Center for Health Workforce Analysis and U.S Census Bureau.
Here is a breakdown of survey respondents’ age:
8.5 percent: younger than 30
10.7 percent: 30-34
11.5 percent: 35-39
10.3 percent: 40-44
11.5 percent: 45-49
9.7 percent: 50-54
12 percent: 55-59
11.9 percent: 60-64
8.5 percent: 65-69
3.4 percent: 70-74
2 percent: 75 or older
https://www.beckershospitalreview.com/workforce/nearly-half-of-rns-were-50-or-older-in-2018.html
Friday, February 14, 2020
BioXcel up as SunTrust beats drum on potential upside
SunTrust’s Robyn Karnauskas is over-the-top bullish on thinly traded micro cap BioXcel Therapeutics (NASDAQ:BTAI) with her $150 (529% upside) price target, an upward revision of 525%.
She says “greater due diligence” revealed added
sales in opioid withdrawal and revised sales potential in dementia,
schizophrenia and bipolar disorder, adding that investors are “missing
the potential” for the impact of results from four clinical trials (two
pivotal and two Phase 2s) to “shift the company’s dynamics.”
The stock is up about six-fold since early November 2019.
Shares up 76% premarket on increased volume.
https://seekingalpha.com/news/3542218-bioxcel-up-76-premarket-suntrust-beats-drum-on-potential-upsideGlobal Cord Blood warns on impact of coronavirus outbreak
In a statement, Global Cord Blood (CO +1.2%)
says the COVID-19 outbreak in China has placed “heavy pressure” on its
sales and marketing efforts due to partial or complete lockdowns in
certain cities in China.
Considering the effects thus far and the
uncertainty in the duration of the outbreak, it expects the situation to
negatively impact fiscal Q4 results (calendar quarter ending March 31),
adding that it may need to revise its fiscal 2021 sales target.
https://seekingalpha.com/news/3542246-global-cord-blood-warns-on-impact-of-coronavirus-outbreakNMC Health’s vice chairman quits as further shareholder twists emerge
NMC Health is still trying to unravel details about the holdings of the company’s top investors, it said on Friday after announcing that one of its controlling shareholders had resigned from the board.
The largest private healthcare provider in the United Arab Emirates
is listed in London on the blue-chip FTSE 100 index but has come under
increasing pressure after shareholder Muddy Waters raised questions over
its finances, prompting major investors to sell out, sending its share
price tumbling.
On Friday NMC said that vice chairman Khalifa Butti Omeir Bin Yousef is stepping down from the board. His resignation came after UK regulators this week said they were looking into the company after news that founder and chairman B.R. Shetty had inaccurately disclosed the size of his stake in the business.
NMC subsequently said on Friday that there had been a series of complex shareholder dealings involving Shetty, Bin Yousef and another top investor, Saeed Butti Al Qebaisi.
The company said Bin Yousef and Al Qebaisi had notified them that some of their shares had been pledged as security for loans by Shetty in an arrangement “they were not party” to.
“The company continues urgently to seek clarity from Dr. B.R. Shetty, Khalifa Bin Butti and H.E. Saeed Bin Butti in relation to the above arrangements and their respective shareholdings,” NMC said.
The disclosure is likely to raise further questions about NMC’s governance and loans taken out by its top shareholders against their stock. Shetty on Monday said that he was stepping back from the board while a legal review of his shareholding disclosures continues.
Al Qebaisi and Bin Yousef on Friday said that an estimated 26 million of the 58.5 million shares they hold have been pledged against loans.
Shares in NMC were down 3.8% at 1351 GMT. The stock has slumped by 70% since Muddy Waters issued a report on Dec. 17 questioning the value of the company’s assets and reported cash balances.
NMC has denied Muddy Waters’ allegations and launched an independent review of its finances.
The company this week said it had received buyout interest from Italian-backed GKSD Investment Holding and United States-based KKR & Co. GKSD subsequently confirmed it could bid for the hospital operator but KKR has said it would not.
On Friday NMC said that vice chairman Khalifa Butti Omeir Bin Yousef is stepping down from the board. His resignation came after UK regulators this week said they were looking into the company after news that founder and chairman B.R. Shetty had inaccurately disclosed the size of his stake in the business.
NMC subsequently said on Friday that there had been a series of complex shareholder dealings involving Shetty, Bin Yousef and another top investor, Saeed Butti Al Qebaisi.
The company said Bin Yousef and Al Qebaisi had notified them that some of their shares had been pledged as security for loans by Shetty in an arrangement “they were not party” to.
“The company continues urgently to seek clarity from Dr. B.R. Shetty, Khalifa Bin Butti and H.E. Saeed Bin Butti in relation to the above arrangements and their respective shareholdings,” NMC said.
The disclosure is likely to raise further questions about NMC’s governance and loans taken out by its top shareholders against their stock. Shetty on Monday said that he was stepping back from the board while a legal review of his shareholding disclosures continues.
Al Qebaisi and Bin Yousef on Friday said that an estimated 26 million of the 58.5 million shares they hold have been pledged against loans.
Shares in NMC were down 3.8% at 1351 GMT. The stock has slumped by 70% since Muddy Waters issued a report on Dec. 17 questioning the value of the company’s assets and reported cash balances.
NMC has denied Muddy Waters’ allegations and launched an independent review of its finances.
The company this week said it had received buyout interest from Italian-backed GKSD Investment Holding and United States-based KKR & Co. GKSD subsequently confirmed it could bid for the hospital operator but KKR has said it would not.
https://www.marketscreener.com/FTSE-100-7392/news/NMC-Health-s-vice-chairman-quits-as-further-shareholder-twists-emerge-29998328/
European stocks climb to record on hopes of limited coronavirus economic hit
Stock markets across the world ticked higher on Friday, as investors bet that the damage to the global economy from China’s coronavirus outbreak would not be long-lasting.
Europe’s broad Euro STOXX 600 hit a record high, gaining 0.1% to mirror gains in Asia after a choppy start to the day.
Indexes in London and Frankfurt gained 0.1% and 0.2% respectively, with the former moving higher after AstraZeneca shares turned positive. The drugmaker had earlier fallen 5% after it said it would take a hit from the coronavirus outbreak.
It was a similar picture in Paris, which clawed back some early losses as Renault shares turned positive. It was last down 0.1%.
Renault had dropped over 4% on its first loss in 10 years as the car company set a lower operating margin goal for 2020, a crunch year for its planned reboot alongside partner Nissan after a scandal surrounding former boss Carlos Ghosn.
Wall Street futures pointed to a slightly higher open.
Chinese health authorities reported more than 5,000 new cases of the disease, with the National Health Commission saying it had recorded 121 new deaths on the mainland on Feb. 13, taking the accumulated total infected to 63,851 people.
Investors said they thought the economic impact of the outbreak would not be as deep as feared, with some also finding succour in a spread beyond China that is not as rapid as feared.
Others have latched on to the possibility of further central bank stimulus measures in response to any slowdown. China’s central bank, for example, has already pumped liquidity into its economy.
“Our base case is that the virus can be largely controlled by end-March,” Mark Haefele, chief investment officer at UBS Global Wealth Management, wrote to clients.
“The negative impact on the economy will be mostly confined to 1Q,” he wrote, predicting that growth would rebound from March on the release of suppressed demand and monetary and fiscal policy support.
MSCI world equity index <.MIWD00000PUS>, which tracks shares in 49 countries, was flat.
Earlier, Asian shares had earlier risen towards their second straight week of gains, helped by hopes governments will make provisions to soften the impact on their economies from the coronavirus epidemic.
MSCI’s broadest index of Asia-Pacific shares outside Japan <.MIAPJ0000PUS> rose 0.1% for a weekly gain of almost 2%. China’s blue-chip CSI300 shares <.CSI300>, meanwhile, rose 0.7%, having staged a stunning recovery to claw back 95% of their losses made after the outbreak.
“China is already easing its monetary policy and providing more liquidity while more stimulus is likely,” said Yukino Yamada, senior strategist at Daiwa Securities.
In its weekly number crunch of markets, analysts at BofA said there had been a record $23.6 billion pumped into bond funds over the last week and big inflows into almost everything else as well.
They also spotted that an interest rate cut in Mexico on Thursday had chalked up the 800th cut by global central banks since the collapse of Lehman Brothers in September 2008. That works out roughly one every five days on average.
Still, some did say they were dialling down bets on equities amid lingering uncertainty on how the crisis would unfold.
“We have actually taken some money out of equities this week,” said Rory McPherson, head of investment strategy at Psigma Investment Management.
“Markets have been overly focused on the good, and not giving a balanced view on whether the stimulus from China isn’t effective.”
EURO BLUES
In currency markets, traders had other matters than the cornoavirus on their minds.
The euro <EUR=EBS> slumped to another near-three-year low, with worries lingering about slowing growth in the euro zone and rising political uncertainties in Germany.
Euro zone growth slowed as expected in the last quarter of 2019 as French and Italian GDP shrank but employment growth picked up more than expected, official estimates showed.
The euro did not waver on the numbers, having earlier fallen to as low as $1.0827.
The single currency last stood flat at $1.08390. It has lost 1% so far this week and is on track for its worst two-weekly performance since mid-2018.
Others market players noted growing demand for the U.S. dollar.
“Investors will surely avoid Asia for the time being and will shift funds to the U.S., geographically the most separated from the region,” said Norihiro Fujito, chief investment strategist at Mitsubishi UFJ Morgan Stanley Securities.
Against a basket of currencies, the dollar hit a four-month high and was last at 99.115. It has risen 1.8% so far this month. The U.S. currency has been trampling everything in its path, including emerging market currencies.
Brazil’s real has hit a record low forcing its central bank to intervene to prop it up, while Turkey’s lira has crumpled to a near nine-month low.
Oil edged higher and was on track for its first weekly gain in six weeks, backed by expectations that producers will implement deeper output cuts to offset slowing demand in China caused by the coronavirus epidemic. Brent crude futures were up 85 cents at $57.19 a barrel.
Indexes in London and Frankfurt gained 0.1% and 0.2% respectively, with the former moving higher after AstraZeneca shares turned positive. The drugmaker had earlier fallen 5% after it said it would take a hit from the coronavirus outbreak.
It was a similar picture in Paris, which clawed back some early losses as Renault shares turned positive. It was last down 0.1%.
Renault had dropped over 4% on its first loss in 10 years as the car company set a lower operating margin goal for 2020, a crunch year for its planned reboot alongside partner Nissan after a scandal surrounding former boss Carlos Ghosn.
Wall Street futures pointed to a slightly higher open.
Chinese health authorities reported more than 5,000 new cases of the disease, with the National Health Commission saying it had recorded 121 new deaths on the mainland on Feb. 13, taking the accumulated total infected to 63,851 people.
Investors said they thought the economic impact of the outbreak would not be as deep as feared, with some also finding succour in a spread beyond China that is not as rapid as feared.
Others have latched on to the possibility of further central bank stimulus measures in response to any slowdown. China’s central bank, for example, has already pumped liquidity into its economy.
“Our base case is that the virus can be largely controlled by end-March,” Mark Haefele, chief investment officer at UBS Global Wealth Management, wrote to clients.
“The negative impact on the economy will be mostly confined to 1Q,” he wrote, predicting that growth would rebound from March on the release of suppressed demand and monetary and fiscal policy support.
MSCI world equity index <.MIWD00000PUS>, which tracks shares in 49 countries, was flat.
Earlier, Asian shares had earlier risen towards their second straight week of gains, helped by hopes governments will make provisions to soften the impact on their economies from the coronavirus epidemic.
MSCI’s broadest index of Asia-Pacific shares outside Japan <.MIAPJ0000PUS> rose 0.1% for a weekly gain of almost 2%. China’s blue-chip CSI300 shares <.CSI300>, meanwhile, rose 0.7%, having staged a stunning recovery to claw back 95% of their losses made after the outbreak.
“China is already easing its monetary policy and providing more liquidity while more stimulus is likely,” said Yukino Yamada, senior strategist at Daiwa Securities.
In its weekly number crunch of markets, analysts at BofA said there had been a record $23.6 billion pumped into bond funds over the last week and big inflows into almost everything else as well.
They also spotted that an interest rate cut in Mexico on Thursday had chalked up the 800th cut by global central banks since the collapse of Lehman Brothers in September 2008. That works out roughly one every five days on average.
Still, some did say they were dialling down bets on equities amid lingering uncertainty on how the crisis would unfold.
“We have actually taken some money out of equities this week,” said Rory McPherson, head of investment strategy at Psigma Investment Management.
“Markets have been overly focused on the good, and not giving a balanced view on whether the stimulus from China isn’t effective.”
EURO BLUES
In currency markets, traders had other matters than the cornoavirus on their minds.
The euro <EUR=EBS> slumped to another near-three-year low, with worries lingering about slowing growth in the euro zone and rising political uncertainties in Germany.
Euro zone growth slowed as expected in the last quarter of 2019 as French and Italian GDP shrank but employment growth picked up more than expected, official estimates showed.
The euro did not waver on the numbers, having earlier fallen to as low as $1.0827.
The single currency last stood flat at $1.08390. It has lost 1% so far this week and is on track for its worst two-weekly performance since mid-2018.
Others market players noted growing demand for the U.S. dollar.
“Investors will surely avoid Asia for the time being and will shift funds to the U.S., geographically the most separated from the region,” said Norihiro Fujito, chief investment strategist at Mitsubishi UFJ Morgan Stanley Securities.
Against a basket of currencies, the dollar hit a four-month high and was last at 99.115. It has risen 1.8% so far this month. The U.S. currency has been trampling everything in its path, including emerging market currencies.
Brazil’s real has hit a record low forcing its central bank to intervene to prop it up, while Turkey’s lira has crumpled to a near nine-month low.
Oil edged higher and was on track for its first weekly gain in six weeks, backed by expectations that producers will implement deeper output cuts to offset slowing demand in China caused by the coronavirus epidemic. Brent crude futures were up 85 cents at $57.19 a barrel.
https://www.marketscreener.com/news/European-stocks-climb-to-record-on-hopes-of-limited-coronavirus-economic-hit–29996808/?countview=0
Bayer Touts Herbicide Research Discovery
Bayer AG said its scientists discovered the building block for a new
herbicide, at a time when the company’s existing weedkillers face legal
and regulatory challenges.
The German seed-and-pesticide supplier said it identified a chemical molecule that has proved effective against grasses that have evolved to survive other herbicides, including Bayer’s Roundup, the world’s top-selling weedkiller. Roundup has for years been losing effectiveness against a rising number of weed species and is the focus of tens of thousands of lawsuits alleging a cancer link, which Bayer is contesting.
Bayer and its rivals are racing to identify and develop new chemical weedkillers after a roughly-three-decade drought in new herbicide discoveries. A decade might pass before Bayer could market its discovery as a new herbicide, Bayer said, since it would require development and regulatory reviews. Bayer said the discovery nevertheless marks a step toward a valuable new agricultural tool, after chemical makers and farmers for decades have relied on existing chemical compounds.
“It’s not like anything else that exists in herbicides,” said Dr. Bob Reiter, Bayer’s head of agricultural research and development.
Bayer’s $5 billion herbicide business is ensnared in tens of thousands of lawsuits filed by plaintiffs alleging that Roundup caused their cancer. The company is contesting those claims, pointing to safety endorsements by regulatory bodies such as the U.S. Environmental Protection Agency, which last month again said Roundup was safe. The company lost the first three cases to go to trial, however, and some countries, including Germany, have moved to ban the herbicide.
Rising research costs and lengthier regulatory reviews played into the lull in developing new herbicides, as did Roundup’s rise to ubiquity in the 1990s. The introduction of crops genetically engineered to survive Roundup and other weedkillers based on the active ingredient glyphosate, made it U.S. farmers’ default spray and led to a lapse in new herbicide research, according to a 2019 paper by Colorado State University Prof. Franck Dayan.
As Roundup’s use soared, weeds evolved to survive it. Swiss pesticide maker Syngenta estimates that glyphosate-resistant weeds will afflict 70% of U.S. soybean fields this year.
Bayer and Corteva Inc., another top seed and chemical supplier, are marketing new herbicide-and-seed combinations to beat back such problem weeds.
Those sprays are based on chemical compounds discovered decades ago, and agricultural researchers have said resistant weeds could overpower those herbicides too. Bayer’s XtendiMax spray, based on the chemical dicamba and approved for sale in 2016, has been blamed for drifting across fields and damaging millions of acres of crops. The company has attributed the majority of complaints to farmers’ own spraying errors.
BASF is preparing to launch this year in Australia what the company said is a new chemical for killing ryegrass. FMC Corp. in 2019 said that in several years it plans to launch a new herbicide for rice farmers battling herbicide-resistant weeds.
Bayer’s newly identified compound is effective against ryegrass and other grasses threatening corn and soybean fields, Dr. Reiter said. Company researchers are working to engineer biotech seeds for such crops as corn, soybeans and cotton that could resist the spray. The potential to develop new sprays and biotech seeds simultaneously was a major factor in Bayer’s $63 billion acquisition of Monsanto in 2018.
While the new herbicide appears to be effective against grasses that can survive Roundup, Dr. Reiter said it wouldn’t replace Roundup’s capacity to kill dozens of weed species.
https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-Touts-Herbicide-Research-Discovery-WSJ-29997964/?countview=0
The German seed-and-pesticide supplier said it identified a chemical molecule that has proved effective against grasses that have evolved to survive other herbicides, including Bayer’s Roundup, the world’s top-selling weedkiller. Roundup has for years been losing effectiveness against a rising number of weed species and is the focus of tens of thousands of lawsuits alleging a cancer link, which Bayer is contesting.
Bayer and its rivals are racing to identify and develop new chemical weedkillers after a roughly-three-decade drought in new herbicide discoveries. A decade might pass before Bayer could market its discovery as a new herbicide, Bayer said, since it would require development and regulatory reviews. Bayer said the discovery nevertheless marks a step toward a valuable new agricultural tool, after chemical makers and farmers for decades have relied on existing chemical compounds.
“It’s not like anything else that exists in herbicides,” said Dr. Bob Reiter, Bayer’s head of agricultural research and development.
Bayer’s $5 billion herbicide business is ensnared in tens of thousands of lawsuits filed by plaintiffs alleging that Roundup caused their cancer. The company is contesting those claims, pointing to safety endorsements by regulatory bodies such as the U.S. Environmental Protection Agency, which last month again said Roundup was safe. The company lost the first three cases to go to trial, however, and some countries, including Germany, have moved to ban the herbicide.
Rising research costs and lengthier regulatory reviews played into the lull in developing new herbicides, as did Roundup’s rise to ubiquity in the 1990s. The introduction of crops genetically engineered to survive Roundup and other weedkillers based on the active ingredient glyphosate, made it U.S. farmers’ default spray and led to a lapse in new herbicide research, according to a 2019 paper by Colorado State University Prof. Franck Dayan.
As Roundup’s use soared, weeds evolved to survive it. Swiss pesticide maker Syngenta estimates that glyphosate-resistant weeds will afflict 70% of U.S. soybean fields this year.
Bayer and Corteva Inc., another top seed and chemical supplier, are marketing new herbicide-and-seed combinations to beat back such problem weeds.
Those sprays are based on chemical compounds discovered decades ago, and agricultural researchers have said resistant weeds could overpower those herbicides too. Bayer’s XtendiMax spray, based on the chemical dicamba and approved for sale in 2016, has been blamed for drifting across fields and damaging millions of acres of crops. The company has attributed the majority of complaints to farmers’ own spraying errors.
BASF is preparing to launch this year in Australia what the company said is a new chemical for killing ryegrass. FMC Corp. in 2019 said that in several years it plans to launch a new herbicide for rice farmers battling herbicide-resistant weeds.
Bayer’s newly identified compound is effective against ryegrass and other grasses threatening corn and soybean fields, Dr. Reiter said. Company researchers are working to engineer biotech seeds for such crops as corn, soybeans and cotton that could resist the spray. The potential to develop new sprays and biotech seeds simultaneously was a major factor in Bayer’s $63 billion acquisition of Monsanto in 2018.
While the new herbicide appears to be effective against grasses that can survive Roundup, Dr. Reiter said it wouldn’t replace Roundup’s capacity to kill dozens of weed species.
https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-Touts-Herbicide-Research-Discovery-WSJ-29997964/?countview=0
AstraZeneca braces for coronavirus hit, but no impact so far
AstraZeneca forecast a likely slowdown in revenue growth this year, assuming a hit from China’s coronavirus epidemic lasting up to a few months, although it added there had been limited disruption to its operations so far.
Shares in the company, one of the world’s major drugmakers, tumbled
as much as 6% in early Friday trade after fourth-quarter results also
missed analysts’ expectations.
However, they recovered after CEO Pascal Soriot played down the impact of the coronavirus outbreak on the business so far. He told Reuters revenues could reach the top end of its guidance range if the epidemic was brought quickly under control.
The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019.
Analysts are currently forecasting growth of 10%, according to Refinitiv data, although Jefferies analysts said anything below a double-digit estimate could be a disappointment.
“We want to be actively conservative in our outlook,” Soriot said on a call with journalists, describing the situation around the virus that has killed more than 1,350 people in China and infected tens of thousands more, as “full of uncertainty.”
“So far, we have limited disruption,” he added.
At 1312 GMT, AstraZeneca shares were down 2.3% at 7,448 pence.
China was once again a key driver for the firm in the final quarter of 2019, with sales there surging 28% to $1.19 billion, making up 19% of total product sales in the period.
“Now in a much better place, AstraZeneca should be able to weather any coronavirus-related storm,” AJ Bell investment director Russ Mould said.
Last week, British rival GSK said it had not faced much disruption to its supply chain from the virus outbreak, but was monitoring the situation.
SALES DISAPPOINT
In the fourth quarter, AstraZeneca’s product sales of $6.25 billion and core earnings of 89 cents per share missed analysts’ expectations, according to a company-provided consensus.
Sales of its top-selling cancer drug Tagrisso fell short of forecasts due to adjustments for U.S. rebates and discounts, Bryan Garnier analyst Eric Le Berrigaud said.
“New drugs which were growth drivers all through 2019 posted below-expectations fourth-quarter sales,” Berrigaud said.
AstraZeneca forecast core earnings per share would rise by a mid- to high-teens percentage in 2020, compared with just 1% in 2019 and analysts’ current consensus forecast of about 20%.
Soriot also said the company was on track to reach an operating profit margin target of more than 30% in 2021.
However, they recovered after CEO Pascal Soriot played down the impact of the coronavirus outbreak on the business so far. He told Reuters revenues could reach the top end of its guidance range if the epidemic was brought quickly under control.
The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019.
Analysts are currently forecasting growth of 10%, according to Refinitiv data, although Jefferies analysts said anything below a double-digit estimate could be a disappointment.
“We want to be actively conservative in our outlook,” Soriot said on a call with journalists, describing the situation around the virus that has killed more than 1,350 people in China and infected tens of thousands more, as “full of uncertainty.”
“So far, we have limited disruption,” he added.
At 1312 GMT, AstraZeneca shares were down 2.3% at 7,448 pence.
China was once again a key driver for the firm in the final quarter of 2019, with sales there surging 28% to $1.19 billion, making up 19% of total product sales in the period.
“Now in a much better place, AstraZeneca should be able to weather any coronavirus-related storm,” AJ Bell investment director Russ Mould said.
Last week, British rival GSK said it had not faced much disruption to its supply chain from the virus outbreak, but was monitoring the situation.
SALES DISAPPOINT
In the fourth quarter, AstraZeneca’s product sales of $6.25 billion and core earnings of 89 cents per share missed analysts’ expectations, according to a company-provided consensus.
Sales of its top-selling cancer drug Tagrisso fell short of forecasts due to adjustments for U.S. rebates and discounts, Bryan Garnier analyst Eric Le Berrigaud said.
“New drugs which were growth drivers all through 2019 posted below-expectations fourth-quarter sales,” Berrigaud said.
AstraZeneca forecast core earnings per share would rise by a mid- to high-teens percentage in 2020, compared with just 1% in 2019 and analysts’ current consensus forecast of about 20%.
Soriot also said the company was on track to reach an operating profit margin target of more than 30% in 2021.
https://www.marketscreener.com/GLAXOSMITHKLINE-9590199/news/AstraZeneca-braces-for-coronavirus-hit-but-no-impact-so-far-29997743/?countview=0
Subscribe to:
Comments (Atom)